ArticleBMC women's health2026
A clinicopathological study of borderline ovarian tumors: insights from a tertiary care center in Saudi Arabia.
Article in BMC women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Preoperative Inflammatory Markers as Predictors of Ovarian Tumor Malignancy: A Retrospective Diagnostic Study.Medicina (Kaunas, Lithuania) · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBorderline ovarian tumors (BOTs) are a distinct category of epithelial ovarian neoplasms characterized by atypical proliferation without stromal invasion. They account for 10–20% of epithelial ovarian malignancies and are typically diagnosed at early stages in younger women. Despite their generally favorable prognosis, regional data remain limited, particularly from Saudi Arabia.
methodsWe conducted a retrospective review of all BOT cases managed at King Faisal Specialist Hospital and Research Center, Jeddah, from January 2015 to February 2025. Clinical, surgical, pathological, and follow-up data were collected and analyzed. Comparative analysis was performed between serous and mucinous subtypes.
resultsA total of 59 patients were included (mean age: 41.8 ± 15.8 years). Most were premenopausal (71.2%) and presented with stage I disease (79.7%). Serous BOT was the predominant subtype (55.9%). Fertility-sparing surgery was performed in 22% of cases. Implants were observed in 25.4%, and microinvasion in 32.2%. Recurrence occurred in 17% of patients, primarily in the contralateral ovary and peritoneum. Serous BOTs were significantly associated with bilateral tumors, higher FIGO stage (p = 0.011), presence of implants (p = 0.038), and recurrence (p = 0.032), while mucinous BOTs showed higher rates of appendectomy and positive peritoneal cytology. Adjuvant therapy was rarely administered and limited to recurrent cases (n = 2/10). Notably, 2 patients (3.4%) died during follow-up, despite the overall favorable prognosis.
conclusionThis study underscores key clinicopathological differences between BOT subtypes and supports surgery as the cornerstone of treatment. Serous BOTs carry a higher risk of recurrence and advanced disease. Tailored surgical strategies and vigilant follow-up are essential, especially in fertility-preserving cases. Further multicenter studies are warranted to guide regional management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.